Patients with atopic dermatitis who had not received biologics prior to treatment with Opzelura were able to avoid biologics ...

The ruxolitinib cream met its primary end point as a treatment for prurigo nodularis in one phase 3 trial but fell short in ...

Two posters presented at the 2025 American Academy of Dermatology Annual Meeting reaffirmed the impact of ruxolitinib cream ...

Incyte’s ruxolitinib franchise, made up of blockbuster JAK inhibitor Jakafi and its topical counterpart Opzelura, have been the company’s driving focus for years. Now, with Jakafi approaching ...

OPZELURA (ruxolitinib cream) has shown strong market growth, driven by increasing adoption in dermatological conditions like vitiligo and atopic dermatitis. Its unique positioning as the first ...

The company's topical cream Opzelura also showed strong growth, with net product revenues jumping 48% YoY to $162 million. "2024 was an important year for Incyte, with a 15% increase in total ...

She was excited to try OPZELURA ® (ruxolitinib) cream 1.5%—a treatment she now prescribes to her appropriate patients. OPZELURA is a non-steroidal, twice-daily cream that is FDA approved for ...

Incyte stock was one of the biggest decliners on the S&P 500 Monday after the drugmaker's fourth-quarter adjusted profit and projections for 2025 sales of key medications fell short of analysts' ...

The stock has declined due to 2025 guidance coming below expectations. Despite slowing sales growth for Jakafi and Opzelura, Incyte's pipeline, with four product launches in 2025 and potential $1B ...

Despite the healthy growth, Incyte provided guidance for leading drugs, Jakafi and Opzelura, that were below expectations. Management expects sales of the hematology drug Jakafi to be between $2. ...

Jakafi Net Sales: $2.8 billion in 2024, up 8% year-over-year. Opzelura Revenue: $508 million in 2024, a 50% increase from 2023. Q4 2024 Revenue: $1.2 billion, up 16% from Q4 2023. Cash Position ...